LOXO-292 clinical trials

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

This study looks at a new drug, selpercatinib, for advanced cancers, including certain lung, thyroid, and other solid tumours that have a specific genetic change called a RET alteration. Researchers want to check its safety, how it works in the body, and if it helps shrink tumours.